New anti-thrombotic drugs for stroke prevention

Current Vascular Pharmacology

Volumn 9, Issue 6, 2011, Pages 723-732

  Di Minno, Matteo Nicola Dario ^a   Russolillo, Anna ^a   Camera, Marina ^b,c   Brambilla, Marta ^c   de Gregorio, Angela ^a   Tremoli, Elena ^b,c   Di Minno, Giovanni ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c CENTRO CARDIOLOGICO MONZINO   (Italy)

Author keywords

Compliance; New antithrombotic drugs; Recommendations; Stroke prevention

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS CLOPIDOGREL; ANTICOAGULANT AGENT; APIXABAN; CILOSTAZOL; CLOPIDOGREL; DABIGATRAN ETEXILATE; PLACEBO; PRASUGREL; RIVAROXABAN; SARPOGRELATE; TERUTROBAN; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; TICLOPIDINE; WARFARIN;

ACUTE CORONARY SYNDROME; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; REVIEW; STROKE; THROMBOEMBOLISM;

AGED; ANTICOAGULANTS; FIBRINOLYTIC AGENTS; HUMANS; MEDICATION ADHERENCE; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; RECURRENCE; SECONDARY PREVENTION; STROKE; VITAMIN K;

EID: 80054077520     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016111797484189     Document Type: Review

References (87)

1. Marsh JD, Keyrouz SG. Stroke prevention and treatment. J Am Coll Cardiol 2010; 56: 683-91.
2. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: The Seventh ACCP Conference on Antithrombotic and Thrombolytic therapy. CHEST 2004; 126: 483S-512S.
3. Hankey GJ. Long-term outcome after ischaemic stroke/transient ischaemic attack. Cerebrovasc Dis 2003; 16 (suppl 1): 14-9.
4. Gensini GF, Zaninelli A, Bignamini AA, et al. SPREAD-Stroke, Prevention and Educational Awareness Diffusion. Italian guidelines for prevention and treatment, January 2010, VI ed. Italy: Publications Catel - Hyperphar Group SpA. Available from http://www.spread.it/node/60
5. Lovelock CE, Cordonnier C, Naka H, et al. Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: a systematic review of published and unpublished studies. Stroke 2010; 41: 1222-8.
6. Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
7. Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am J Med 2008; 121: 43-9.
8. Gent M, Easton JD, Ellis DJ, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 19: 442-3.
9. Hass WK, Easton DJ, Adams HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients: Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989; 321: 501-7.
10. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003; 108: 1682-7.
11. Aronow HD, Steinhubl SR, Brennan DM, et al. Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J 2009; 157: 369-74.
12. CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel vs. aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
13. Sudlow CL, Mason G, Maurice JB, Wedderburn CJ, Hankey GJ. Thienopyridine derivatives vs. aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database Syst Rev 2009; CD001246.
14. Angiolillo DJ. Variability in responsiveness to oral antiplatelet therapy. Am J Cardiol 2009; 103 (3 suppl): 27A-34A.
15. Coccheri S. Antiplatelet drugs--do we need new options? With a reappraisal of direct thromboxane inhibitors. Drugs 2010; 70: 887-908.
16. Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin "resistance" and risk of cardiovascular morbidity: a systematic review and meta-analysis. BMJ 2008; 336: 195-8.
17. Sofi F, Marcucci AR, Gori AM, et al. Clopidogrel nonresponsiveness and risk of cardiovascular morbidity. An updated metanalysis. Thromb Haemost 2010; 103: 841-8.
18. Maree AO, Curtin RJ, Chubb A, et al. Cycloxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 2005; 3: 2340-5.
19. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-62.
20. Tabassome S, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-75.
21. Motovska Z, Widimsky P, Kvasnicka J, et al. High loading dose of clopidogrel is unable to satisfactorily inhibit platelet reactivity in patients with glycoprotein IIIA gene polymorphism: a genetic substudy of PRAGUE-8 trial. Blood Coagul Fibrinolysis 2009; 20: 257-62.
22. Mehta SR, Bassand JP, Chrolavicius S, et al. Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Am Heart J 2008; 156: 1080-8.
23. Di Minno G, Silver MJ, Cerbone AM, Murphy S. Trial of repeated low-dose aspirin in diabetic angiopathy. Blood 1986; 68: 886-91.
24. Gupta S, Gupta MM. Aspirin and clopidogrel resistance -myth or reality: an update. Indian Heart J 2008; 60: 245-53.
25. Gibson CM. Antiplatelet therapy: anti-ischemic benefits vs. bleeding risk. J Interv Cardiol 2008; 21 (suppl 1):S3-9.
26. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180-9.
27. Alberts MJ, Bhatt DL, Mas JL, et al. Three-Year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. Eur Heart J 2009; 30: 2318-26.
28. Toso V, Carolei A, Gensini GF, et al. The stroke in Italy and related impact on outcome (SIRIO) study: design and baseline data. Neurol Sci 2006; 27: S263-S267.
29. Leoo T, Lindgren A, Petersson J, von Arbin M. Risk factors and treatment at recurrent stroke onset: Results from the Recurrent Stroke Quality and Epidemiology (RESQUE) Study. Cerebrovasc Dis 2008; 25: 254-60.
30. Angiolillo DJ, Bhatt DL, Gurbel PA, et al. Advances in antiplatelet therapy: agents in clinical development. Am J Cardiol 2009; 103 (Suppl): 40A-51A.
31. Cattaneo M. ADP receptors antagonists. In: Michelson AD, Ed. Platelet. San Diego, CA: Academic Press 2006; pp. 1127-44.
32. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007; 153: 66.e9-16.
33. Sugidachi A, Ogawa T, Kurihara A, et al. The greater antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J Thromb Haemost 2007; 5: 1545-51.
34. Wiviott SD, Antman EM, Gibson CM, et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J 2006; 152: 627-35.
35. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel vs. clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15.
36. Van Giezen JJ, Nilsson L, Berntsson P, et al. Ticagrelor binds to the human P2Y (12) receptor independently from ADP but antagonizes ADP induced receptor signaling and platelet aggregation. J Thromb Haemost 2009; 7: 1556-65.
37. Geiger J, Brich J, Honig-Liedl P, et al. Specific impairment of human platelet P2Y (AC) ADP receptor mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol 1999; 19: 2007-11.
38. Trumel C, Payrastre B, Plantavid M, et al. A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase. Blood 1999; 94: 4156-65.
39. Wihlborg AK, Wang L, Braun OO, et al. ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contrac tion in human blood vessels. Arterioscler Thromb Vasc Biol 2004; 24: 1810-5.
40. Anderson SD, Shah NK, Yim J, Epstein BJ. Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist. Ann Pharmacother 2010; 44: 524-37.
41. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27: 1038-47.
42. James S, Akerblom A, Cannon CP, et al. Comparison of ticagrelor, the first reversible oral P2Y (12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009; 157: 599-605.
43. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-57.
44. Bhatt DL. Intensifying platelet inhibition-navigating between Scylla and Charybdis. N Engl J Med 2007; 357: 2078-81.
45. Sorbera LA, Serradell N, Bolos J, Bayes M. Terutroban sodium. Prostanoid tp receptor antagonist, antithrombotic agent, antiatherosclerotic agent. Drugs Future 2006; 31: 867-73.
46. Viles-Gonzales JF, Fuster V, Corti R, et al. Atherosclerosis regression and TP receptor inhibition: effect of S 18886 on plaque size and composition - a magnetic resonance imaging study. Eur Heart J 2005; 26: 1557-61.
47. Fiessinger JN, TAIPAD Study Group. S18886, a new specific TP receptor antagonist is safe and as effective as aspirin in inhibiting platelet aggregation in patients with peripheral arterial disease. Eur Heart J 2004; 25: 89-90.
48. Bousser MG, Amarenco P, Chamorro A, et al. Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30mg/day vs. aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. Cerebrovasc Dis 2009; 27: 509-18.
49. Shinohara Y, Nishimaru K, Sawada T, for S-ACCESS Study Group. Sarpogrelate-SarpoAspirin comparative clinical study for efficacy and safety in secondary prevention of cerebral infarction (S-ACCESS): a randomized, double-blind, aspirin controlled trial. Stroke 2008; 39: 1827-33.
50. Angiolillo DJ, Capranzano P, Goto S, et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur Heart J 2008; 29: 2202-11.
51. Kamal AK, Naqvi I, Husain MR, Khealani BA. Cilostazol vs. aspirin for secondary prevention of vascular events after stroke of arterial origin. Cochrane Database Syst Rev 2011; CD008076.
52. Hart G, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have non-valvular atrial fibrillation. Ann Intern Med 2007; 146: 857-67.
53. Fang MC, Stafford RS, Ruskin JN, Singer DE. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation Arch Intern Med 2004; 164: 55-60.
54. Marcucci M, Iorio A, Nobili A, et al. Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards. Eur J Int Med 2010; 21: 516-23.
55. Brass L, Krumholz L, Scinto J, et al. Warfarin use following ischemic stroke among medicare patients with atrial fibrillation. Arch Intern Med 1998; 158: 2093-100.
56. Connolly SJ, Pogue J, Hart RG, et al.; ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360: 2066-78.
57. The ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin vs. oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903-12.
58. Lafuente C, Mahe I, Extramiana F. Management of atrial fibrillation. BMJ 2009; 339: b5216.
59. Perez-Gomez F, Alegria E, Berjon J, et al.; NASPEAF Investigators. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and non-valvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol 2004; 44: 1557-66.
60. Vedovati MC, Becattini C, Agnelli G. Combined oral anticoagulants and antiplatelets: benefits and risks. Intern Emerg Med 2010; 5: 281-90.
61. Singer DE, Albers GW, Dalen JE, et al. American College of Chest Physicians: Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 546S-92S.
62. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulation. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1998; 114: 445S-69S.
63. Halperin JL. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with non-valvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003; 146: 431-8.
64. Lee CJ, Badhwar G, Ansell JE. Oral IIa inhibitors. Hematol Oncol Clin North Am 2010; 24: 739-53.
65. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with non-valvular atrial fibrillation (PETRO Study). Am J Cardiol 2007; 100: 1419-26.
66. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran vs. warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
67. Kubitza D, Becka M, Voith B, et al. Safety pharmacodynamics and pharmacokinetics of BAY39-7959, an oral direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78:412-21.
68. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors development. Clin Pharmacokinet 2009; 48: 1-22.
69. Kubitza D, Becka M, Wensing G, et al. Safety pharmacodynamics and pharmacokinetics of BAY39-7959, an oral direct factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61: 873-80.
70. Kakar P, Watson T, Lip GY. Rivaroxaban. Drugs Today (Barc) 2007; 43: 129-36.
71. Kubitza D, Haas S. Novel factor Xa inhibitors for the prevention and treatment of thromboembolic diseases. Expert Opin Investig Drugs 2006; 15: 843-55.
72. Ufer M. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost 2010; 103: 572-85.
73. Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban vs. placebo in patients with acute coronary syndromes (Atlas ACS-TIMI 46): a randomized double blind, phase II trial. Lancet 2009; 374: 29-38.
74. The Executive Steering Committee, on behalf of the ROCKET AF Study Investigators. Rivaroxaban-Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study. Am Heart J 2010; 159: 340-7.
75. Weits JI, Bates SM. New anticoagulants. J Thromb Haemost 2005; 3: 1843-53.
76. Turpie AGG. Oral direct Factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 2007; 27: 1238-47.
77. Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and selective factor Xa inhibitor:, antithrombotic and antihemostatic studies. J Thromb Haemost 2007; 6: 820-9.
78. Wang L, Zhang D, Raghavan N, et al. assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 2010; 38: 448-58.
79. Lopes RD, Alexander JH, Al-Khatib SM, et al. Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010; 159: 331-9.
80. Eikelboom J W, O'Donnell M, Yusuf S, et al. Rationale and design of AVERROES: Apixaban vs. acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable forvitamin K antagonist treatment. Am Heart J 2010; 159: 348-53.
81. Ahrens I, Lip GYH, Peter K. What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation? Thromb Haemost 2011; 105: 574-8.
82. Peterson ED, Roe MT, Mulgund J, et al. Association between hospital process performance and outcomes among patients with acute coronary syndromes. JAMA 2006; 295: 1912-20.
83. Gresele P, Falcinelli E, Momi S. Potentiation and priming of platelet activation: a potential target for antiplatelet therapy. Trends Pharmacol Sci 2008; 29: 352-60.
84. Manfioletti G, Brancolini C, Avanzi G, Schneider C. The protein encoded by a growth arrest specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative co-regulator in the blood coagulation cascade. Mol Cell Biol 1993; 13: 4976-85.
85. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 2001; 89: 201-10.
86. Otterdal K, Pedersen TM, Solum NO. Release of soluble CD40 ligand after platelet activation. Studies on the solubilization phase. Thromb Res 2004; 114: 167-77.
87. Ma H, Hara A, Xiao CY, et al. Increased bleeding tendency and decreased susceptibility to thromboembolism in mice lacking the prostaglandin E2 receptor subtype EP3. Circulation 2001; 104: 1176-80.